

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8052572

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RUNSHENG LI	01/07/2021
WENTAO HUANG	01/07/2021
RECEIVING PARTY DATA	
Name:	LANOVA MEDICINES DEVELOPMENT CO., LTD
Street Address:	NO. 177, GROUP 6, RENNAN VILLAGE
Internal Address:	KANGQIAO TOWN, PUDONG NEW DISTRICT
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201315
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17685029
CORRESPONDENCE DATA	
Fax Number:	(301)398-9306
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	301-398-0000
Email:	patents@astrazeneca.com
Correspondent Name:	ASTRAZENECA
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	GPRC5D-100-US-PCT[2]
NAME OF SUBMITTER:	ANNMARIE JEZIORO
SIGNATURE:	/Annmarie Jezioro/
DATE SIGNED:	07/12/2023
Total Attachments: 2	
source=Assignment_70LG-325887-WO_Fully Executed#page1.tif	
source=Assignment_70LG-325887-WO_Fully Executed#page2.tif	

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

LANOVA MEDICINES DEVELOPMENT CO., LTD.
No. 177, Group 6, Rennan Village
Kangqiao Town, Pudong New District
Shanghai 201315, China

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for all countries in and to this invention relating to

ANTI-GPRC5D MONOCLONAL ANTIBODIES AND USES THEREOF

as set forth in PCT International Application

check one ☐ executed concurrently herewith,
 ☐ executed on _____,
 ☒ Serial No.: PCT/CN2021/070314 Filed January 5, 2021

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent all countries for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in all countries, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, (e) all post-grant proceedings including but not limited to post-grant review, ex parte reexamination and inter partes review, and (f) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY GRANTS ASSIGNEE the right to sue for past, present and future infringement, and the right to collect and receive any damages, royalties, or settlement for such past, present and future infringements and any and all causes of action relating to any of the inventions or discoveries described in this invention.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR/INVENTOR(S):

Signature: Runsheng Li

Name: Runsheng Li

Date: Jan. 7. 2021

Signature: Wentao Huang

Name: Wentao Huang

Date: Jan. 7. 2021

ASSIGNEE:

Signature: 

Name: Ying Qin Zang

Title: CEO

Date: Jan. 7, 2021